These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 27996999

  • 1. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].
    Colonna P, Ammirati F, a nome del Gruppo Italiano eXperience.
    G Ital Cardiol (Rome); 2016 Nov; 17(11):932-939. PubMed ID: 27996999
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.
    Circulation; 2015 Sep 29; 132(13):1252-60. PubMed ID: 26199338
    [Abstract] [Full Text] [Related]

  • 3. CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban.
    Peacock WF, Tamayo S, Patel M, Sicignano N, Hopf KP, Yuan Z.
    Ann Emerg Med; 2017 May 29; 69(5):541-550.e1. PubMed ID: 27913059
    [Abstract] [Full Text] [Related]

  • 4. Design and Rationale of the RELAXED (Recurrent Embolism Lessened by rivaroxaban, an Anti-Xa agent, of Early Dosing for acute ischemic stroke and transient ischemic attack with atrial fibrillation) Study.
    Yasaka M, Minematsu K, Toyoda K, Yamagami H, Yoshimura S, Nagao T, Mori E, Hirano T, Hamasaki T, Yamaguchi T.
    J Stroke Cerebrovasc Dis; 2016 Jun 29; 25(6):1342-8. PubMed ID: 26987488
    [Abstract] [Full Text] [Related]

  • 5. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    Cerebrovasc Dis; 2019 Jun 29; 48(1-2):53-60. PubMed ID: 31578012
    [Abstract] [Full Text] [Related]

  • 6. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial Fibrillation for the Regulation of Coagulation (STAR) Study.
    Engelberger RP, Noll G, Schmidt D, Alatri A, Frei B, Kaiser WE, Kucher N.
    Eur J Intern Med; 2015 Sep 29; 26(7):508-14. PubMed ID: 25935131
    [Abstract] [Full Text] [Related]

  • 7. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S, Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, Murakawa Y, Iwashiro S, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S.
    J Stroke Cerebrovasc Dis; 2020 Apr 29; 29(4):104584. PubMed ID: 31983518
    [Abstract] [Full Text] [Related]

  • 8. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE, Fox KA, Patel MR.
    Circulation; 2016 Jan 26; 133(4):352-60. PubMed ID: 26673560
    [Abstract] [Full Text] [Related]

  • 9. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.
    Spencer RJ, Amerena JV.
    Am J Cardiovasc Drugs; 2015 Dec 26; 15(6):395-401. PubMed ID: 26062914
    [Abstract] [Full Text] [Related]

  • 10. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P, Giugliano RP.
    J Cardiovasc Pharmacol Ther; 2014 Nov 26; 19(6):526-32. PubMed ID: 24659084
    [Abstract] [Full Text] [Related]

  • 11. Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.
    Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP.
    Int J Cardiol; 2018 Apr 15; 257():78-83. PubMed ID: 29506743
    [Abstract] [Full Text] [Related]

  • 12. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.
    Alberts M, Chen YW, Lin JH, Kogan E, Twyman K, Milentijevic D.
    Stroke; 2020 Feb 15; 51(2):549-555. PubMed ID: 31888412
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
    Cerezo-Manchado JJ, Navarro-Almenzar B, Elvira-Ruiz G, García-Candel F, Flores-Blanco PJ, Caro-Martínez C, Manzano-Fernández S, García-Iniesta N, Sánchez-García J, Cabañas-Perianes V, Moraleda-Jiménez JM.
    Future Cardiol; 2018 May 15; 14(3s):31-37. PubMed ID: 29848091
    [Abstract] [Full Text] [Related]

  • 14. The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.
    Hurley C, Dai S, Sobieraj DM.
    Int J Cardiol; 2015 Aug 01; 192():1-2. PubMed ID: 25981569
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
    Barón-Esquivias G, Fernández-Avilés F, Atienza F, Pastor Pueyo P, Toro R, Sanmartín Fernández M.
    Expert Rev Cardiovasc Ther; 2015 Apr 01; 13(4):341-53. PubMed ID: 25797900
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, Fox KA, ROCKET AF Steering Committee and Investigators.
    Am Heart J; 2015 Oct 01; 170(4):675-682.e8. PubMed ID: 26386791
    [Abstract] [Full Text] [Related]

  • 17. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP, Dadashzadeh ER, Cheung J, Alarcon L, Kutcher M, Brown JB, Neal MD.
    J Trauma Acute Care Surg; 2017 Mar 01; 82(3):542-549. PubMed ID: 28045742
    [Abstract] [Full Text] [Related]

  • 18. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH, Cappato R, Ezekowitz MD, Evers T, Sahin K, Kirchhof P, Meng IL, van Eickels M, Camm AJ, X-VeRT Steering Committee and Investigators.
    Europace; 2016 Feb 01; 18(2):184-90. PubMed ID: 26487668
    [Abstract] [Full Text] [Related]

  • 19. Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
    Burgos KD, Sienko SE, Hoffman JL, Koerber JM, Smythe MA.
    Clin Appl Thromb Hemost; 2018 Mar 01; 24(2):372-378. PubMed ID: 28301906
    [Abstract] [Full Text] [Related]

  • 20. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
    Brun Guinda D, Callen García Ó, Ondiviela Pérez J, Gracia Aznarez M, Artero Bello P, Rivero Fernandez E, Marquina Barcos A, Villarroel Salcedo M.
    Future Cardiol; 2018 May 01; 14(3s):39-45. PubMed ID: 29848090
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.